IART
Integra LifeSciences Holdings Corporation
Healthcare · Medical Devices · NMS
$16.99
Data: 2026-05-28
✓ ETHICAL PASS

Unknown MOAT
HIGH
Data Confidence: 85.7%
Key Metrics

How this company measures up on the fundamentals that matter

Market Cap
$1.2B
Total market value of the company
5.82
Based on estimated future earnings — lower means cheaper
Rev Growth
+2.4%
Year-over-year revenue change
Profit Margin
-30.1%
How much profit the company keeps from each dollar of revenue
-38.6%
Return on equity — how efficiently it uses shareholder money
Analyst Target
$14.00
-18% from current price — median analyst estimate
Recommendation
HOLD
Consensus view from 7 analysts covering this stock
About Integra LifeSciences Holdings Corporation

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical, ear, nose, throat, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates through Codman Specialty Surgical and Tissue Technologies segments. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment. It also offers after-market services; surgical headlamps and instrumentation; instrument patterns and surgical and lighting products to hospitals, surgery centers, dental, podiatry, and veterinary offices. In addition, the company provides treatment of acute wounds, such as burns; chronic wounds, including diabetic foot ulcers; and surgical tissue repair applications, including hernia reinforcement, tendon protection, and peripheral nerve repair. Further, it offers skin and wound repair, plastics and surgical reconstruction products, and nerve and tendon repair products. Additionally, the company is involved in the ear, nose, and throat business that includes instrumentation, balloon technologies for sinus dilation and eustachian tube dilation, and surgical navigation systems. It offers its products directly through various salesforces and other distribution channels to the hospitals, integrated health networks, group purchasing organizations, clinicians, surgery centers, and health care providers in the United States, Europe, the Asia Pacific, and internationally. Integra LifeSciences Holdings Corporation was formerly known as Integra LifeSciences Corp. and changed its name to Integra LifeSciences Holdings Corporation in June 1995. Integra LifeSciences Holdings Corporation was incorporated in 1989 and is headquartered in Princeton, New Jersey.

https://www.integralife.com

Country: United States Employees: 4,427 Industry: Medical Devices
Ethical Screening

Five compliance checks based on AAOIFI standards — all must pass for ethical clearance

Business Activity
PASS
Core business does not involve prohibited activities
Debt Ratio
0.0% N/A
Debt must be below 33% of total assets
Cash Ratio
0.0% N/A
Interest-bearing cash below 33% of assets
Receivables
0.0% N/A
Receivables below 49% of assets
Revenue Purity
0.0% PASS
Non-compliant revenue below 5% — any excess requires purification
Quantitative Intelligence

Statistical analysis of price behaviour, risk, and market regime — independent of fundamental data

MARKUP
Price trending up with increasing momentum
-0.186
Returns do not compensate for the risk — negative edge
-0.0308
No positive edge detected — the data suggests staying out
-0.355
Drawdown risk outweighs the returns — higher risk profile
Annual Return
-25.6%
Historical annualised return based on price data
-72.1%
Largest peak-to-trough decline — the worst it has been
SIDEWAYS
Price consolidating — no clear directional bias
Days in State
16
How long the current regime has persisted — longer means more stable
Market Data

Trading characteristics and market positioning

1.08
Moves slightly more than the broader market
52W High
$16.49
-3% below the year high
52W Low
$8.70
95% above the year low
Avg Volume
964,922
Average daily shares traded — higher means easier to buy and sell
8.1
Days it would take all short sellers to cover — higher means more crowded
Short % Float
16.3%
Elevated short interest — bears are positioned against this
N/A
Annual dividend as a percentage of the share price
$-6.47
Earnings per share over the last 12 months
Financial Health

Balance sheet strength and cash generation — the foundation of long-term value

195.79
Heavy leverage — higher financial risk if revenues decline
3.38
Strong balance sheet — comfortably covers short-term obligations
Quick Ratio
1.53
Like current ratio but excludes inventory — stricter test
Gross Margin
56.7%
Revenue left after cost of goods — higher means pricing power
Operating Margin
10.4%
Profit from core operations before interest and tax
$69M
Positive — the business generates more cash than it spends
Revenue (TTM)
$1.6B
Total revenue over the last 12 months
Net Income
$-495,798,016
Loss-making — spending exceeds revenue after all costs
Analyst Coverage
Analysts
7
Target High
$27.00
Target Median
$14.00
Target Low
$11.00
Explore the Ethical Screener View Track Record

Data sourced from public filings and market feeds. Not financial advice. Updated: 2026-05-28

Discover More
Alpha Insights Market Intelligence Titan Watch Ethical Screener Insider Intelligence Track Record Ethical Finance Zakat Calculator Iran Oil Tracker Foundry (292 articles) Indicators Join Free →

Get our weekly market brief free.